Q-omics provides the consensus-scored S100A11P9 profile across patient tissues and cancer cell-line models. S100A11P9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, S100A11P9 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, S100A11P9 RNA expression shows 7,752 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where S100A11P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A11P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A11P9 survival associations across molecular data types. S100A11P9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A11P9 RNA expression–survival associations across cancer types. High S100A11P9 expression shows unfavorable associations in MESO, KICH, THCA, LIHC, ACC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for S100A11P9 RNA expression.
This table summarizes S100A11P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for S100A11P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A11P9 shows higher tumor expression in HNSC, LUSC and COAD. The HNSC box plot shows higher S100A11P9 RNA expression in tumor versus normal tissue (log2 FC = +0.147, t-test p = .010).
This table shows molecular features associated with S100A11P9 in patient tissues and cancer cell lines. In patient samples, S100A11P9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
